Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

STLN vs ICU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICU Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–1 Matrix Metrics)

ICU Overall Winner 6-Pillar Tally: STLN 1 – 3 ICU (2 Tie) Matrix Metrics: STLN 1 – 7 ICU

As of Nov 20, 2026, SeaStar Medical Holding Corporation (ICU) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas ICU carries 49.6/100 (HOLD) at $0.94 (N/M Forward P/E, -816.6% operating margin).

  • Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile ICU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STLN vs ICU
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 175% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 26
RSI-14: 26.4 · SMA20: $4.93 · SMA50: $5.93
ICU NASDAQ Head-to-Head Winner
SeaStar Medical Holding Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.94
-10.95% 1D
Market Cap $5.6M
TTM Revenue $1.7M
Forward P/E N/M
Beta / 30D Vol 1.41β · 216% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.1%), weak momentum, RSI 28
RSI-14: 27.6 · SMA20: $1.72 · SMA50: $2.72

6-Pillar Scorecard Institutional Category Breakdown (STLN 1 – 3 ICU)

Columns: Metric · STLN · ICU
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ICU
Revenue Growth (YoY) N/A +82.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $1.7M
Market Cap N/A $5.6M
3. Profitability & Quality ICU
Gross Margin N/A 92.6%
Operating Margin N/A -816.6%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -356.9%
4. Balance Sheet & Cash Flow ICU
Cash Generation (TTM) N/A -$14M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $6.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STLN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STLN (1) vs ICU (7)
Institutional Metric STLN ICU Criterion Row Edge
Market Capitalization
Scale
N/A $5.6M Larger Scale ICU
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +82.0% Higher Growth ICU
Operating Margin (TTM)
Profitability
N/A -816.6% Higher Margin ICU
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ICU
Return on Equity (ROE)
Capital Efficiency
N/A -356.9% Higher ROE ICU
52-Week Range Position
Momentum
1% ($3–$7) 14% ($0–$5) Stronger Trend ICU
Beta / 30D Volatility
Risk Regime
1.42β · 175% Vol 1.41β · 216% Vol Lower Realized Risk STLN
Unified Institutional Score
Composite Signal
46.6 / 100 (HOLD) 49.6 / 100 (HOLD) Higher Composite ICU
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 92.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$14M ($6.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STLN +10.61 pp
STLN: -56.58% · ICU: -67.19%
3M Horizon STLN +19.63 pp
STLN: -51.06% · ICU: -70.69%
6M Horizon STLN +28.72 pp
STLN: -41.97% · ICU: -70.69%
1Y Horizon STLN +28.72 pp
STLN: -41.97% · ICU: -70.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs ICU. Trailing 12-month operating profitability (STLN N/A vs ICU -816.6%) and valuation multiples (STLN N/M vs ICU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STLN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ICU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.7M
Gross Margin92.6%
Op. Margin-816.6%
ROE / Fwd P/E-356.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ICU BREAKDOWN
133d in phase · OBV DISTRIBUTION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ICU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STLN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ICU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.6M market capitalization and -816.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STLN vs ICU Key Questions & Quantitative Answers

As of Nov 20, 2026, SeaStar Medical Holding Corporation (ICU) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas ICU carries 49.6/100 (HOLD) at $0.94 (N/M Forward P/E, -816.6% operating margin). Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile ICU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ICU leads the Growth & Scale pillar: STLN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ICU at +82.0% YoY revenue growth and +0.0% YoY earnings growth on $1.7M TTM revenue (92.6% gross margin, -816.6% operating margin). On trailing 12-month operating scale, STLN generates N/A in USD-normalized revenue versus $1.7M for ICU. In operating R&D and SG&A reinvestment, STLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ICU.

STLN and ICU trade at balanced relative valuation multiples. STLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ICU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STLN (N/A ROE) versus ICU (-356.9% ROE) capital efficiency.

In options market volatility and institutional positioning, STLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 175% Vol realized risk). By comparison, ICU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 216% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.